Jianqin Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianqin Lu has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Song Li
University of Pittsburgh
13 shared publications Yixian Huang
13 shared publicationsJiang Li
Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA
11 shared publications- Xiang Gao
Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China
10 shared publications - Zhiren Wang
Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, USA
10 shared publications Raman Venkataramanan
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA
9 shared publications
Latest Publications
- 12 November 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer
Camptothecin (CPT) is a potent Topoisomerase I (TOP1) inhibitor that induces DNA damage through the formation of TOP1-DNA–protein cross-links (TOP1-DPCs). Despite its promising anticancer activity, the clinical translation of CPT has been limited by lactone instability, rapid clearance, off-target toxicities, and unfavorable pharmacokinetics. To overcome these limitations, we previously developed Camptothesome, a sphingomyelin-conjugated CPT nanovesicle that stabilizes the active lactone form of CPT, prolongs circulation, enhances tumor accumulation, and improves therapeutic efficacy against colorectal cancer (CRC). However, cancer cells can repair TOP1-DPCs through a neddylation-dependent pathway, reducing their sensitivity to CPT. To address this mechanism, we developed C-pevosome, a dual-drug liposomal nanoplatform that codelivers CPT and the NEDD8-activating enzyme inhibitor pevonedistat (PEV) at an optimized synergistic ratio. By simultaneously inducing TOP1-DPC formation and blocking neddylation-mediated repair, C-pevosome enhanced DNA damage, apoptosis, tumor accumulation, and antitumor efficacy while reducing systemic toxicity. To further improve intratumoral delivery, we engineered AzC-pevosome by incorporating a tumor-acidic pH-responsive charge-reversal phospholipid, which promoted cellular uptake, tumor penetration, and intratumoral distribution. Consequently, AzC-pevosome further enhanced therapeutic efficacy and sensitized tumors to immune checkpoint blockade, resulting in superior tumor suppression in advanced orthotopic CRC models. This strategy holds strong potential to improve therapeutic efficacy, safety, and patient compliance in CRC treatment.
- 12 November 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer
Camptothecin (CPT) is a potent Topoisomerase I (TOP1) inhibitor that induces DNA damage through the formation of TOP1-DNA–protein cross-links (TOP1-DPCs). Despite its promising anticancer activity, the clinical translation of CPT has been limited by lactone instability, rapid clearance, off-target toxicities, and unfavorable pharmacokinetics. To overcome these limitations, we previously developed Camptothesome, a sphingomyelin-conjugated CPT nanovesicle that stabilizes the active lactone form of CPT, prolongs circulation, enhances tumor accumulation, and improves therapeutic efficacy against colorectal cancer (CRC). However, cancer cells can repair TOP1-DPCs through a neddylation-dependent pathway, reducing their sensitivity to CPT. To address this mechanism, we developed C-pevosome, a dual-drug liposomal nanoplatform that codelivers CPT and the NEDD8-activating enzyme inhibitor pevonedistat (PEV) at an optimized synergistic ratio. By simultaneously inducing TOP1-DPC formation and blocking neddylation-mediated repair, C-pevosome enhanced DNA damage, apoptosis, tumor accumulation, and antitumor efficacy while reducing systemic toxicity. To further improve intratumoral delivery, we engineered AzC-pevosome by incorporating a tumor-acidic pH-responsive charge-reversal phospholipid, which promoted cellular uptake, tumor penetration, and intratumoral distribution. Consequently, AzC-pevosome further enhanced therapeutic efficacy and sensitized tumors to immune checkpoint blockade, resulting in superior tumor suppression in advanced orthotopic CRC models. This strategy holds strong potential to improve therapeutic efficacy, safety, and patient compliance in CRC treatment.
- Open Access
- 4 September 2026
- Published by Tsinghua University Press in Nano Research
- Vol. 19 (11)
Strategic integration of saturated phospholipids into Camptothesome to enhance colorectal cancer chemo-immunotherapy
Colorectal cancer (CRC) remains largely unresponsive to immune checkpoint blockade (ICB), with therapeutic benefit confined to a small subset of high immunogenic tumors, underscoring the need for effective combination strategies. Chemotherapy-induced immunogenic cell death (ICD) combined with immune modulation offers a promising therapeutic strategy for malignant cancers, including CRC; however, its clinical translation remains constrained by poor drug solubility, suboptimal pharmacokinetics, inadequate tumor delivery, and systemic toxicity. Previously, we developed Camptothesome-based co-delivery nanosystem that integrates a doxorubicin-indoximod (DOX-IND) conjugate with a sphingomyelin-derived camptothecin (SM-CPT), which simultaneously induced robust ICD and blocked indoleamine 2,3-dioxygenase 1 (IDO1)-mediated immunosuppression, enhancing anti-CRC efficacy. However, this formulation failed to produce sufficient efficacy in more advanced orthotopic CRC tumors. Here, we report a rational phospholipid engineering strategy to optimize this nanoplatform by incorporating four FDA-approved phospholipids, DOPC, DSPC, HSPC, and SPC at varying molar ratios to systematically tune bilayer physicochemical properties. Saturated phospholipids (DSPC and HSPC), markedly enhanced cellular uptake, IDO1 inhibition, ICD induction, and T cell proliferation. Among them, DSPC-containing nanoformulation was superior in co-delivering payloads to tumor, and boosted antitumor efficacy and immune responses in advanced metastatic CRC mouse model. Furthermore, the DSPC-fortified DOX-IND/Camptothesome potentiated the ICB to eradicate the more advanced and immune-cold CRC tumors. These findings establish phospholipid-driven membrane engineering as a key determinant of Camptothesome-based chemo-immunotherapy performance and provide a clinically translatable strategy to enhance ICB responsiveness in CRC.
- 4 September 2026
- Published by Tsinghua University Press in Nano Research
- Vol. 19 (11)
Open AccessStrategic integration of saturated phospholipids into Camptothesome to enhance colorectal cancer chemo-immunotherapy
Colorectal cancer (CRC) remains largely unresponsive to immune checkpoint blockade (ICB), with therapeutic benefit confined to a small subset of high immunogenic tumors, underscoring the need for effective combination strategies. Chemotherapy-induced immunogenic cell death (ICD) combined with immune modulation offers a promising therapeutic strategy for malignant cancers, including CRC; however, its clinical translation remains constrained by poor drug solubility, suboptimal pharmacokinetics, inadequate tumor delivery, and systemic toxicity. Previously, we developed Camptothesome-based co-delivery nanosystem that integrates a doxorubicin-indoximod (DOX-IND) conjugate with a sphingomyelin-derived camptothecin (SM-CPT), which simultaneously induced robust ICD and blocked indoleamine 2,3-dioxygenase 1 (IDO1)-mediated immunosuppression, enhancing anti-CRC efficacy. However, this formulation failed to produce sufficient efficacy in more advanced orthotopic CRC tumors. Here, we report a rational phospholipid engineering strategy to optimize this nanoplatform by incorporating four FDA-approved phospholipids, DOPC, DSPC, HSPC, and SPC at varying molar ratios to systematically tune bilayer physicochemical properties. Saturated phospholipids (DSPC and HSPC), markedly enhanced cellular uptake, IDO1 inhibition, ICD induction, and T cell proliferation. Among them, DSPC-containing nanoformulation was superior in co-delivering payloads to tumor, and boosted antitumor efficacy and immune responses in advanced metastatic CRC mouse model. Furthermore, the DSPC-fortified DOX-IND/Camptothesome potentiated the ICB to eradicate the more advanced and immune-cold CRC tumors. These findings establish phospholipid-driven membrane engineering as a key determinant of Camptothesome-based chemo-immunotherapy performance and provide a clinically translatable strategy to enhance ICB responsiveness in CRC.
- Open Access
- 11 May 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (23) , 11294-11310
Artificial recombinant high-density protein nanocarriers for precision drug delivery
Chemically programmable reconstituted HDL nanocarriers for drug delivery.
- 11 May 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (23) , 11294-11310
Open AccessArtificial recombinant high-density protein nanocarriers for precision drug delivery
Chemically programmable reconstituted HDL nanocarriers for drug delivery.
- Open Access
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy
Eliciting calreticulin (CRT) surface exposure is essential for triggering immunogenic cell death (ICD). However, stanniocalcin 1 (STC1) suppresses CRT translocation by sequestering it within mitochondria, limiting ICD induction in tumours. Here, we show that silencing STC1 enhances CRT surface exposure in Lewis lung carcinoma (LLC) cells when combined with paclitaxel (PTX), converting dying tumour cells into an in-situ vaccine that drives immunoprevention of tumour growth. To maximize this therapeutic synergy, we engineered a nanoplatform co-delivering siSTC1 and PTX, in which PTX is covalently conjugated to a sphingolipid and siSTC1 is electrostatically encapsulated (siSTC1/LNP-PTX). This system improves pharmacokinetics, synchronizes co-delivery to tumours, and enhances intratumoral exposure. Consequently, it amplifies CRT expression, promotes antigen-presenting cell-mediated phagocytosis and antigen presentation, and elicits robust cytotoxic T cell responses in LLC models. Moreover, siSTC1/LNP-PTX sensitizes tumours to PD-1 blockade. Our nanosystem, which unlocks ICD potential by silencing STC1, represents a paradigm-shifting approach to cancer immunotherapy.
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBoosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy
Eliciting calreticulin (CRT) surface exposure is essential for triggering immunogenic cell death (ICD). However, stanniocalcin 1 (STC1) suppresses CRT translocation by sequestering it within mitochondria, limiting ICD induction in tumours. Here, we show that silencing STC1 enhances CRT surface exposure in Lewis lung carcinoma (LLC) cells when combined with paclitaxel (PTX), converting dying tumour cells into an in-situ vaccine that drives immunoprevention of tumour growth. To maximize this therapeutic synergy, we engineered a nanoplatform co-delivering siSTC1 and PTX, in which PTX is covalently conjugated to a sphingolipid and siSTC1 is electrostatically encapsulated (siSTC1/LNP-PTX). This system improves pharmacokinetics, synchronizes co-delivery to tumours, and enhances intratumoral exposure. Consequently, it amplifies CRT expression, promotes antigen-presenting cell-mediated phagocytosis and antigen presentation, and elicits robust cytotoxic T cell responses in LLC models. Moreover, siSTC1/LNP-PTX sensitizes tumours to PD-1 blockade. Our nanosystem, which unlocks ICD potential by silencing STC1, represents a paradigm-shifting approach to cancer immunotherapy.
- Open Access
- 9 December 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 55 (2) , 1008-1038
Biomimetic liposomes in drug delivery: from design mechanisms to applications
This review summarizes advances in biomimetic liposome-based delivery systems, highlighting design strategies such as membrane integration and applications in targeted therapy, imaging, immunomodulation, gene delivery, and vaccines.
- 9 December 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 55 (2) , 1008-1038
Open AccessBiomimetic liposomes in drug delivery: from design mechanisms to applications
This review summarizes advances in biomimetic liposome-based delivery systems, highlighting design strategies such as membrane integration and applications in targeted therapy, imaging, immunomodulation, gene delivery, and vaccines.
- Open Access
- 21 August 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (10) , 1734-1753
A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer
Taxol and Abraxane, the US Food and Drug Administration-approved paclitaxel (PTX) formulations, have revealed hypersensitivity due to excipients and mediocre efficacy due to insufficient tumor penetration, respectively. Here we developed a sphingolipid-derived PTX nanovesicle (paclitaxome) via covalently conjugating PTX to sphingomyelin, which improved pharmacokinetics and enhanced efficacy in metastatic triple-negative breast cancer and pancreatic cancer female mice and reduced myelosuppression. To bolster tumor penetration and reduce phagocytosis, we engineered a cationization-enabled transcytosis machinery by installing an ultra-pH-sensitive azepane (AZE) probe into paclitaxome and masked nanovesicle surface with a CD47 ‘self’ peptide (CD47p). The resulting CD47p/AZE–paclitaxome synchronized the co-delivery of gemcitabine or carboplatin to boost tumor inhibition and eradicate metastasis in late-stage KPC-Luc pancreatic cancer model and prevent tumor relapse and extend survival in postsurgical 4T1-Luc2 triple-negative breast cancer model in female mice. CD47p/AZE–paclitaxome also outperformed previous promising PTX nanoformulations. Finally, the series of nanoparticle modifications was applied to camptothecin, demonstrating its generalizability.
- 21 August 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (10) , 1734-1753
Open AccessA sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer
Taxol and Abraxane, the US Food and Drug Administration-approved paclitaxel (PTX) formulations, have revealed hypersensitivity due to excipients and mediocre efficacy due to insufficient tumor penetration, respectively. Here we developed a sphingolipid-derived PTX nanovesicle (paclitaxome) via covalently conjugating PTX to sphingomyelin, which improved pharmacokinetics and enhanced efficacy in metastatic triple-negative breast cancer and pancreatic cancer female mice and reduced myelosuppression. To bolster tumor penetration and reduce phagocytosis, we engineered a cationization-enabled transcytosis machinery by installing an ultra-pH-sensitive azepane (AZE) probe into paclitaxome and masked nanovesicle surface with a CD47 ‘self’ peptide (CD47p). The resulting CD47p/AZE–paclitaxome synchronized the co-delivery of gemcitabine or carboplatin to boost tumor inhibition and eradicate metastasis in late-stage KPC-Luc pancreatic cancer model and prevent tumor relapse and extend survival in postsurgical 4T1-Luc2 triple-negative breast cancer model in female mice. CD47p/AZE–paclitaxome also outperformed previous promising PTX nanoformulations. Finally, the series of nanoparticle modifications was applied to camptothecin, demonstrating its generalizability.
- Open Access
- 1 July 2025
- Published by Tsinghua University Press in Nano Research
- Vol. 18 (7)
Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines
Peptide-based vaccines only contain peptide epitopes and exclude unnecessary biological materials, which greatly reduces the risk of causing an undesired immune response and further improves the safety profile, garnering considerable interest in vaccine development. However, the immunogenicity induced by these peptides alone is not potent enough to elicit an effective immune response. Recently, combining the adjuvants with peptide antigens has shown promising effects to realize a satisfying immune response. In this review, we discuss the development of immunoadjuvants to enhance the safety and efficacy of peptide-based vaccines. The emphasis is placed on the application and clinical translation of nanotechnology-based adjuvants, highlighting the associated challenges and exploring future directions.
- 1 July 2025
- Published by Tsinghua University Press in Nano Research
- Vol. 18 (7)
Open AccessAdvances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines
Peptide-based vaccines only contain peptide epitopes and exclude unnecessary biological materials, which greatly reduces the risk of causing an undesired immune response and further improves the safety profile, garnering considerable interest in vaccine development. However, the immunogenicity induced by these peptides alone is not potent enough to elicit an effective immune response. Recently, combining the adjuvants with peptide antigens has shown promising effects to realize a satisfying immune response. In this review, we discuss the development of immunoadjuvants to enhance the safety and efficacy of peptide-based vaccines. The emphasis is placed on the application and clinical translation of nanotechnology-based adjuvants, highlighting the associated challenges and exploring future directions.
- 14 May 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 200, 629-640
Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32
- 14 May 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 200, 629-640
Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32
- 18 February 2025
- Published by Wiley in Small Methods
- Vol. 9 (8) , e2402154
Liposome‐Enabled Nanomaterials for Muscle Regeneration
Muscle regeneration is a vital biological process that is crucial for maintaining muscle function and integrity, particularly for the treatment of muscle diseases such as sarcopenia and muscular dystrophy. Generally, muscular tissues can self‐repair and regenerate under various conditions, including acute or chronic injuries, aging, and genetic mutation. However, regeneration becomes challenging beyond a certain threshold, particularly in severe muscle injuries or progressive diseases. In recent years, liposome‐based nanotechnologies have shown potential as promising therapeutic strategies for muscle regeneration. Liposomes offer an adaptable platform for targeted drug delivery due to their cell membrane‐like structure and excellent biocompatibility. They can enhance drug solubility, stability, and targeted delivery while minimizing systemic side effects by different mechanisms. This review summarizes recent advancements, discusses current applications and mechanisms, and highlights challenges and future directions for possible clinical translation of liposome‐based nanomaterials in the treatment of muscle diseases. It is hoped this review offers new insights into the development of liposome‐enabled nanomedicine to address current limitations.
- 18 February 2025
- Published by Wiley in Small Methods
- Vol. 9 (8) , e2402154
Liposome‐Enabled Nanomaterials for Muscle Regeneration
Muscle regeneration is a vital biological process that is crucial for maintaining muscle function and integrity, particularly for the treatment of muscle diseases such as sarcopenia and muscular dystrophy. Generally, muscular tissues can self‐repair and regenerate under various conditions, including acute or chronic injuries, aging, and genetic mutation. However, regeneration becomes challenging beyond a certain threshold, particularly in severe muscle injuries or progressive diseases. In recent years, liposome‐based nanotechnologies have shown potential as promising therapeutic strategies for muscle regeneration. Liposomes offer an adaptable platform for targeted drug delivery due to their cell membrane‐like structure and excellent biocompatibility. They can enhance drug solubility, stability, and targeted delivery while minimizing systemic side effects by different mechanisms. This review summarizes recent advancements, discusses current applications and mechanisms, and highlights challenges and future directions for possible clinical translation of liposome‐based nanomaterials in the treatment of muscle diseases. It is hoped this review offers new insights into the development of liposome‐enabled nanomedicine to address current limitations.
- Open Access
- 25 November 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (2) , 834-851
Size-transformable nanotherapeutics for cancer therapy
- 25 November 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (2) , 834-851
Open AccessSize-transformable nanotherapeutics for cancer therapy